ProteinQure Inc.
25.3.2024 05:03:30 CET | ACCESS Newswire | Press release
TORONTO, ON / ACCESSWIRE / March 25, 2024 / ProteinQure, the leading startup in the computational design of peptide drugs, announces a significant breakthrough in the fight against triple-negative breast cancer (TNBC). The novel Peptide Drug Conjugate (PDC) designed by ProteinQure demonstrated exceptional efficacy in a comprehensive suite of Patient-Derived Xenograft (PDX) models. The experiments were conducted in the lab of Dr. David Cescon at the Princess Margaret Cancer Centre/University Health Network, one of the world's top five cancer research centres.
Developed through ProteinQure's cutting-edge computational platform, the innovative SORT1 targeting PDC is a novel peptide attached to a highly potent chemotherapeutic agent. The drug candidate was tested across a broad range of breast cancer models. The results demonstrated remarkable antitumor efficacy, including cancers resistant to standard chemotherapies and antibody-drug conjugates.
"Working with the David Cescon Lab at UHN has been instrumental in validating our novel PDC's efficacy against one of the most challenging forms of breast cancer. Based on these results, we are moving our lead program forward into IND-Enabling studies and our first clinical trial," said Lucas Siow, CEO of ProteinQure. "These findings not only highlight the power of our computational drug design platform but also represent significant validation in our quest to develop tissue-specific peptides for targeted drug delivery."
ProteinQure's collaborators will present the data at the upcoming American Association for Cancer Research (AACR) conference in San Diego. The AACR conference, renowned for showcasing the latest innovations in cancer research, provides the perfect stage to share these findings with the global cancer research community.
"We are excited to present this data at AACR and help develop new therapeutic options for breast cancer, especially with promising Canadian startups," stated Dr. David Cescon, head of the lab at UHN. "The success of this unique PDC in diverse PDX models is a testament to the potential of combining advanced computational techniques, precision oncology, and our labs' robust preclinical platform".
Funding for parts of this work included contributions from IRAP-Canada and the INOVAIT program based out of Sunnybrook Hospital.
Poster Presentation Details:
Title: In-vivo efficacy of a novel peptide-conjugated drug in patient-derived xenograft models of breast cancer
Session Title: New Targets
Date and Time: Tuesday, April 9, at 1:30 p.m. PT/4:30 p.m. ET
Abstract Number: 5911
Speaker: Mitchell Elliott, UHN Princess Margaret Cancer Centre
About ProteinQure
ProteinQure is a pioneering startup specializing in the computational design of peptide drugs utilizing state-of-the-art artificial intelligence and molecular simulation technologies. With a focus on precision medicine, ProteinQure is dedicated to transforming the landscape of drug development and ushering in a new era of targeted effective treatments.
About the David Cescon Lab at UHN
The David Cescon Lab at the University Health Network is a leader in breast cancer research, focusing on the mechanisms of cancer progression and resistance to therapy. Through cutting-edge pre-clinical and clinical research and collaborations, the lab develops novel therapeutic strategies aimed at improving outcomes for cancer patients worldwide.
For further information, please contact:
Lucas Siow - CEO of ProteinQure - press@proteinqure.com
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
SOURCE: ProteinQure Inc.
View the original press release on accesswire.com
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
POLARIS Laboratories Joins the Dow Coolant Care Network as Testing Provider for DOWFROST Heat Transfer Fluids28.5.2026 15:00:00 CEST | Press release
INDIANAPOLIS, IN / ACCESS Newswire / May 28, 2026 / POLARIS Laboratories® today announced Dow has selected POLARIS Laboratories® as a testing provider for DOWFROST™ LC and HD Heat Transfer Fluids used in advanced cooling systems. This collaboration reinforces Dow's commitment to helping customers move beyond reactive maintenance practices toward proactive, data-driven fluid management. DOWFROST™ Heat Transfer Fluids are engineered to support next-generation data center cooling, including direct-to-chip liquid cooling architectures. Formulated with high-purity propylene glycol and advanced inhibitor technology, these fluids enable efficient heat removal, corrosion protection, and long-term operational stability in high-performance computing environments. To meet thermal demands from Artificial Intelligence (AI) and high-density computing, monitoring liquid cooling fluid is critical to protect uptime, maintain performance and reduce operational risk. The Dow Coolant Care Network integrat
Caldwell Strengthens Financial Services and Fintech Capabilities with Addition of Alex Langridge in London28.5.2026 10:30:00 CEST | Press release
TORONTO, ON AND LONDON, UK / ACCESS Newswire / May 28, 2026 / Retained executive search firm Caldwell (TSX:CWL)(OTCQX:CWLPF) today announced the addition of Alex Langridge as a Partner in the firm's Financial Services Practice. Based in London, Langridge advises clients across financial services and fintech on senior executive and board appointments, succession planning, organizational design, and transformational leadership hiring. Based in London, Alex Langridge joins Caldwell's Financial Services Practice, bringing deep expertise across banking, fintech, insurance, and transformational leadership advisory. Langridge brings more than 20 years of executive search and leadership advisory experience, partnering with banks, insurers, fintechs, and private equity- and venture-backed businesses across the UK and EMEA. He is particularly known for placing P&L, operations, commercial, product, technology, and digital leaders into high-impact transformational roles, as well as for helping cli
Applications are Open for the 2026 Semmelweis-Richter Journalism Award Until June 9th28.5.2026 09:00:00 CEST | Press release
BUDAPEST, HUNGARY / ACCESS Newswire / May 28, 2026 / After the strong success of its first edition, the Semmelweis-Richter Journalism Award returns in 2026. Journalists from eligible European countries are invited to submit entries in two categories: Women's Health and Pharmaceutical Strategies and Innovation, with a special focus on cardiovascular therapies. The application deadline is June 9, 2026, 23:59 CET. The international award was first launched in 2025 by Semmelweis University, Hungary's leading medical and health sciences university, with the support of Gedeon Richter, a Hungary-based, innovation-focused multinational pharmaceutical company. The award aims to recognise high-quality health journalism and its role in informing the public and shaping health-related debate across Europe. The first edition attracted wide international interest, with nearly 70 submissions from more than 20 European countries, including the United Kingdom, Germany, and Russia. Entries were published
Miami Fashion Week Successfully Launches Inaugural Virtual Fashion Awards Gala at Queen Miami Beach27.5.2026 18:00:00 CEST | Press release
A groundbreaking evening celebrating the future of fashion through technology, creativity, and innovation brought together global designers, AI-powered runway premieres, and industry recognition. MIAMI, FL / ACCESS Newswire / May 27, 2026 / Miami Fashion Week (MIAFW) successfully hosted its inaugural Virtual Fashion Awards on May 21, 2026, at Queen Miami Beach, hosted by Emmy Award-Winning Journalist, Lisa Petrillo. The exclusive in-person event welcomed global fashion leaders, designers, and innovators for an evening dedicated to creativity, technology, and the evolving future of fashion. Blending physical and digital experiences, the gala featured both produced and in-development collections, highlighting the fusion of emerging technologies with traditional craftsmanship. A live model showcase complemented the AI-powered virtual runway presentations, creating a fully immersive experience for attendees. Images (Courtesy of Miami Fashion Week): here Official Gala Recap and Virtual Pres
OMP Launches Unison Express to Fast-Track Supply Chain Planning from Ambition to Early Value27.5.2026 15:00:00 CEST | Press release
Ready-to-deploy solution delivers value quickly through proven industry best practices ANTWERPEN, BE / ACCESS Newswire / May 27, 2026 / OMP, a leading provider of AI-powered supply chain planning solutions, today announced the launch of Unison Express - an industry-specific, ready-to-deploy planning offering for mid-market companies looking to move beyond the tools and processes they have outgrown. Unison Express enables teams to realize value quickly while establishing a strong planning foundation that scales with their business over time. From spreadsheets to structured planning Organizations across industries face mounting pressure to modernize supply chain planning. Yet implementation projects can feel long, costly, and difficult to justify, especially when teams still rely on tools and processes they have outgrown, such as spreadsheets, legacy systems, and manual coordination. The result is higher operational risk and slower, less coordinated decision-making. Unison Express bridge
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom